Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression

BMC Urology

Volumn 12, Issue , 2012, Pages

  Byler, Timothy K ^a   Leocadio, Dean ^a   Shapiro, Oleg ^a   Bratslavsky, Gennady ^a   Stodgell, Christopher J ^b   Wood, Ronald W ^b   Messing, Edward M ^b   Reeder, Jay E ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Bladder cancer; Gene expression; Thrombospondin 1, Urothelial carcinoma; Valproic acid

Indexed keywords

HISTONE DEACETYLASE; RNA; THROMBOSPONDIN 1; VALPROIC ACID; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINARY TRACT CANCER; UROTHELIUM CANCER;

CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; THROMBOSPONDIN 1; UP-REGULATION; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; VALPROIC ACID;

EID: 84864913315     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-12-21     Document Type: Article

References (21)

1. SEER Public-Use 1973-2002, Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Public-Use Data (1973-2002). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2005, based on the November 2004 submission
2. EUA Guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M, Eur Urol 2011 59 997 1008 10.1016/j.eururo.2011.03.017 21458150
3. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V, J Neurooncol 2007 85 159 170 10.1007/s11060-007-9402-7 17534580 (Pubitemid 47629397)
4. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragano M, Boccuzzi G, J Endocrinol 2006 191 465 472 10.1677/joe.1.06970 17088416 (Pubitemid 44830622)
5. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Blood 2007 110 2302 2308 10.1182/blood-2007-03-078576 17596541 (Pubitemid 47523148)
6. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Kakshmanan Y, Yung BYM, Lupold SE, Rodriguez R, Cortes J, Wierda WG, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Gardia-Manero G, J Pharmacol Exp Ther 2006 319 533 542 10.1124/jpet.106.106658 16868035
7. Differential effects of valproic acid on growth proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines. Byun SS, Kim FJ, Khandrika L, Kumar B, Koul S, Wilson S, Koul HK, Cancer Lett 2009 281 196 202 10.1016/j.canlet.2009.02.045 19324494
8. Inhibition of bladder tumour growth by histone deacetylase inhibitor. Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N, Yokoyama M, BJU Int 2010 105 1181 1186 10.1111/j.1464-410X.2009.08795.x 19681894
9. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Vallo S, Xi W, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA, Anti-Cancer Drugs 2011 22 1002 1009 21822119
10. Three distinct D-amino acid substitutions confer potent anti-angiogenic activity on an inactive peptide dervived from a Thrombospondin-1 type 1 repeat. Dawson DW, Volpert OV, Pearce FA, Schneider AJ, Silverstein RL, Henkin J, Bouck N, Mol Pharmacol 1999 55 332 338 9927626 (Pubitemid 29076031)
11. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ, JNCI 1997 89 219 227 10.1093/jnci/89.3.219 9017002 (Pubitemid 27073759)
12. Molecular mediators of angiogenesis in bladder cancer. Campbell SC, Bolpert OV, Ivanovich M, Bouck NP, Cancer Res 1998 58 1298 1304 9515819 (Pubitemid 28183222)
13. Androgeneic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. Johnson AM, OConnell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE, BMC Urol 2008 8 7 10.1186/1471-2490-8-7 18433501 (Pubitemid 351712920)
14. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR, Cancer Res 1999 52 3512 3517 (Pubitemid 29334516)
15. Normalization of real-time quantitative reverse transcription-PCR data: A model based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data. Andersen CL, Jensen JL, Orntoft TF, Cancer Res 2004 64 5245 5250 10.1158/0008-5472.CAN-04-0496 15289330 (Pubitemid 39006544)
16. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F, Genome Biol 2002 3 1 12
17. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
18. Thrombospondin-1 expression in Urothelial carcinoma: prognostic significance and association with p53 alerations, tumour angiogenesis, and extracellular matrix components. Ioachim E, Michael MC, Salmas M, Damala K, Tsanou E, Michael MM, Malamou-Mitsi V, Stavropoulos NE, BMC Cancer 2006 6 140 10.1186/1471-2407-6-140 16732887 (Pubitemid 44219124)
19. Valproic Acid inhibits angiogenesis in vitro and in vivo. Michaelis M, Michaelis R, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffman K, Kotchetkov R, Busse R, Nau H, Cinatl J, Mol Pharmacol 2004 65 520 527 10.1124/mol.65.3.520 14978230 (Pubitemid 38264019)
20. Lexi-Comp Inc. (Lexi-Drugs), Lexi-Comp, Inc June 1, 2012
21. Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line. Kwiecinska P, Tauboll E, Gregoraszczuk EL, Pharmacol Rep 2012 64 157 165 22580532